NM_000075.4(CDK4):c.4G>A (p.Ala2Thr) AND Hereditary melanoma

Clinical significance:Uncertain significance (Last evaluated: Nov 8, 2018)

Review status:1 star out of maximum of 4 stars

criteria provided, single submitter

Based on:
1 submission [Details]
Record status:
current
Accession:
RCV000805427.1

Allele description [Variation Report for NM_000075.4(CDK4):c.4G>A (p.Ala2Thr)]

NM_000075.4(CDK4):c.4G>A (p.Ala2Thr)

Gene:
CDK4:cyclin dependent kinase 4 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
12q14.1
Genomic location:
Preferred name:
NM_000075.4(CDK4):c.4G>A (p.Ala2Thr)
HGVS:
  • NC_000012.12:g.57751714C>T
  • NG_007484.2:g.5668G>A
  • NM_000075.4:c.4G>AMANE SELECT
  • NP_000066.1:p.Ala2Thr
  • LRG_490:g.5668G>A
  • NC_000012.11:g.58145497C>T
  • NM_000075.3:c.4G>A
Protein change:
A2T
Links:
dbSNP: rs1483991096
NCBI 1000 Genomes Browser:
rs1483991096
Molecular consequence:
  • NM_000075.4:c.4G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary melanoma
Synonyms:
Hereditary cutaneous melanoma; Familial melanoma
Identifiers:
MONDO: MONDO:0018961; MedGen: C1512419

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000945383Invitaecriteria provided, single submitter
Uncertain significance
(Nov 8, 2018)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240-242.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Invitae, SCV000945383.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This sequence change replaces alanine with threonine at codon 2 of the CDK4 protein (p.Ala2Thr). The alanine residue is moderately conserved and there is a small physicochemical difference between alanine and threonine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with CDK4-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The threonine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 7, 2021

Support Center